Table 2 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternatives
Medication | Monthly cost after deductible | Monthly cost in gap | Monthly cost in catastrophic | ||||||
|---|---|---|---|---|---|---|---|---|---|
Median of state mean costs | Median of state mean costs | Median of state mean costs | |||||||
$, (Range of mean costs) | $, (Range of mean costs) | $, (Range of mean costs) | |||||||
2007 | 2011a | Change (%) | 2007 | 2011a | Change (%) | 2007 | 2011a | Change (%) | |
Arimidex/Anastrozole | 39.64 (38.37–48.19) | 9.57 (8.00–11.95) | −76 | 258.64 (247.44–263.47) | 38.94 (31.80–78.46) | −85 | 13.18 (12.68–13.32) | 3.72 (3.39–6.19) | −72 |
Aromasin/Exemestane | 42.57 (40.72–50.94) | 49.50 (42.34–118.68) | +16 | 267.56 (255.21–273.62) | 244.51 (228.61–270.95) | −9 | 13.66 (13.07–13.79) | 14.41 (13.51–71.41) | +6 |
Femara/Letrozole | 41.92 (39.38–51.11) | 69.31 (59.69–85.17) | +65 | 277.65 (249.14–282.54) | 225.13 (209.10–252.23) | −19 | 14.16 (12.96–14.34) | 38.53 (33.70–57.15) | +172 |
Tamoxifen | 6.19 (5.95–9.22) | 5.54 (5.12–6.89) | −11 | 21.32 (20.36–25.42) | 13.17 (12.44–21.11) | −38 | 2.26 (2.20–2.70) | 2.73 (2.50–3.47) | +21 |